U.S., Nov. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07231029) titled 'A Pharmacokinetic Study of TS-172 in Patients With Hepatic Impairment' on Nov. 13.
Brief Summary: An open-label study to evaluate the effect of TS-172 administration on pharmacokinetics in patients with hepatic impairment
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
Patients With Mild or Moderate Hepatic Impairment
Intervention:
DRUG: TS-172
Single oral administration of TS-172 20mg
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Taisho Pharmaceutical Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....